Navigation Links
Abbott Receives CE Mark Certification

The CE Mark certification has been received by the global healthcare company Abbott towards a new test for detecting the Neissera gonorrhoeae (NG) and Chlamydia trachomatis // (CT) sexually transmitted pathogens. This will enable the company to sell the product in the European Union (EU). The test will be conducted through the Abbott m2000?, which uses real time polymerase chain reaction (PCR) and magnetic particle technology.

Where sexually transmitted diseases are concerned, gonorrhea and chlamydia are the most common, and accurate detection of these diseases can serve to avoid serious illness at a later stage. The European laboratories will be able to get highly reliable test results through the combination of the Abbott m2000 system and the Abbott RealTime? CT/NG assay. The amplified nucleic acid tests can be done on urine samples in a non-invasive manner. Processes like molecular tests, sample preparation and data analysis are automated through the use of the m2000.

As many as 300 million sexually transmitted diseases infections occur across the world annually, according to the World Health Organization (WHO), of which gonorrhea accounts for 55 million and chlamydia accounts for another 85 million. No symptoms are seen in the case of these diseases in 10% of the men and 80% of the women who are infected, even though they are fully capable of infecting others with the disease.

If they are not properly treated, it can result in serious complications like urethritis, sterility, and pelvic inflammatory diseases. Antibiotics are capable of curing both the strains of the disease. Abbott has an alliance with the Celera Diagnostics in Europe through which the test will be made available. Tests are being conducted to detect the hepatitis B virus and HIV/AIDS also through the Abbott m2000 system.
'"/>




Page: 1

Related medicine news :

1. Pharmacia may take 51.5 percent Abbott stake
2. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
3. Abbott’s Laboratories R&D Capabilities Questione
4. Abbott to Subsidize Price of HIV Drug
5. Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt
6. Fifth US Patient Receives Artificial Heart
7. Northfield Labs Receives FDA Comments
8. British MPs Say Prostate Cancer Receives Low Priority in the NHS
9. Zactima Receives Fast Track Designation By The FDA
10. East London Receives World Class New Private Hospital Facility
11. Brinda Karat Receives Legal Notice over Ramdev Issue
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/2/2016)... MA (PRWEB) , ... May 02, 2016 , ... Pregnancy ... tips when trying to conceive. , “If you are ready to have ... Mache Seibel. “My book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, a new company ... automate and improve the rapid diagnosis, triage and admission of patients leveraging IBM ... and mobile experience for the first time at GENBAND’s Perspectives16 conference. , ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... ... Research & Analytics EVP and GM Jim Callandrillo and Duane Reed, VP ... 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General Meeting ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased ... Model Could Transform the Pharma Landscape .” CMS recently proposed a test of alternate ... provider-administered drugs while preserving care provided to beneficiaries. The webinar will review the details ...
(Date:5/2/2016)... , ... May 02, 2016 , ... For many artists, ... artist Curt Walter has developed it into a science. , Using the new, ... achieve subtly differentiated shades that add depth and meaning to his works. What’s more, ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
Breaking Medicine Technology: